MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
0.3894
-0.0206
-5.02%
Pre Market: 0.4080 +0.0186 +4.78% 09:14 12/15 EST
OPEN
0.4009
PREV CLOSE
0.4100
HIGH
0.4700
LOW
0.3661
VOLUME
717
TURNOVER
0
52 WEEK HIGH
1.730
52 WEEK LOW
0.2649
MARKET CAP
13.92M
P/E (TTM)
-0.6645
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AKTX last week (1208-1212)?
Weekly Report · 12h ago
Akari Therapeutics announces preclinical data on AKTX-101
TipRanks · 6d ago
Akari Therapeutics Reports Its AKTX-101 Shows Potent Preclinical Activity Against K-Ras G12V Pancreatic Cancer Cells
Benzinga · 6d ago
AKARI THERAPEUTICS PLC - PLANS FIRST-IN-HUMAN TRIAL FOR AKTX-101 IN LATE 2026
Reuters · 6d ago
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
Barchart · 6d ago
Akari Therapeutics Prepares Investor Presentation for Conferences
TipRanks · 12/08 13:33
Weekly Report: what happened at AKTX last week (1201-1205)?
Weekly Report · 12/08 10:37
Akari Therapeutics provides update, highlights ADC payload innovation
TipRanks · 12/04 14:16
More
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.